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ABSTRACT
Oxidative stress, which is an early determinant of Alzheimer’s disease (AD), is involved in mediating neuronal apoptosis in
Aβ-induced cell death. C60 fullerenes are known to behave like a “radical sponge” as they can sponge up free radicals and act more
effectively than other antioxidants. PEG-C60 -3, a C60 fullerene derivative, was investigated against β-amyloid (Aβ)25-35-induced toxicity
toward Neuro-2A cells in this study. PEG-C60 -3 reduced Aβ25-35-induced cytotoxicity, which showed an increasing cell viability with C60
and Aβ25-35 co-treated cells. Moreover, the intracellular reactive oxygen species (ROS) accumulation caused by Aβ-treated Neuro-2A
cells was reduced by PEG-C60 -3 co-treatment. Microarray for the analysis of gene expressions was investigated. Endoplasmic reticulum (ER) stress responsive genes, ion-channel, cell-cycle and anti-oxidant related cell responses were found to be associated with
C60 protective mechanism against Aβ25-35 treatment. The results offered new comprehension into the possible pathway of Aβ25-35 gene
expression and C60 protective mechanism. With the understanding of the roles of Aβ and C60 in cells, we can hopefully provide insight
on therapeutic design using C60 fullerene nanoparticles against Aβ-associated diseases.
Key words: apoptosis, amyloid, fullerene, reactive oxygen species (ROS)

INTRODUCTION
Amyloid plaques are protein deposits found abundantly
in the brains of Alzheimer's patients. The plaques, along
with neurofibrillary tangles, interfere with normal neuron
functioning. Over the past decade, several hypotheses have
been set forth to explain the pathophysiology of AD(1). The
mechanisms underlying AD and the events responsible for its
progression remain unclear. It was confirmed that oxidative
stress is involved in apoptotic mechanisms where production
of excessive reactive oxidative species (ROS) can mediate
neuronal apoptosis in Aβ-induced cell death, resulting in
senile plaque formation(2). Once Aβ peptide aggregates into
amyloid fibrils with a cross β-sheet conformation, the fibril
became neurotoxic partly due to the generation of its associated free radicals, followed by lipid peroxidation and protein
oxidation as a result of oxidative stress(3). Oxidant-induced
oligomerization of Aβ is recognized as an important factor
in neuronal dysfunction and cellular apoptosis. Thus, antioxidants are used to prevent and cure associated diseases.
* Author for correspondence. Tel: 886-2-27361661 ext. 3165;
Fax: 886-2-27387348; E-mail: cmlin@tmu.edu.tw
# Thess two authors contributed equally to this work.

Water-soluble C60 fullerene derivatives have been
significantly studied due to the broad range of biological
activities found for these compounds. It also has been shown
to exhibit considerable in vitro biological activities, including
cytotoxic, site-selective DNA cleavage and inhibition of HIV
protease(4). The exceptional radical-scavenging property
of fullerene makes it a promising pharmacophore to target
diseases caused by the overexpression of radicals(5,6). When
injected intravenously, it is distributed rapidly to various
tissues and most of the material is retained in the body after
one week. The fullerene molecules rapidly aggregate in
water but disaggregate after entering the membrane interior.
The compound was also able to penetrate the blood-brain
barrier (BBB)(4,7). The C60 fulleropyrrolidine-thalidomide
dyad (CLT) is an effective agent for suppressing the release
of NO and TNF-α by the LPS-stimulated macrophages
RAW264.7(8). The fulleropyrrolidine-xanthine dyad can
effectively suppress LPS-induced NO production(9). These
results suggest the possibility of using C60 fullerene or
fullerene dyad for treatment to support the pharmacological
and non-pharmacological therapy of AD.
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MATERIALS AND METHODS
I. Chemicals and Reagents
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium
bromide (MTT) and dihydrorhodamine 123 (DHR123) were
purchased from Sigma (St. Louis, MO, USA). All solvents
used in this study were from Merck (Darmstadt, Germany).
Dulbecco’s modified Eagle’s medium (DMEM), penicillin
and streptomycin were obtained from Gibco BRL (Grand
Island, NY, USA). The water-soluble C60 fullerene (PEGC60 -3) was prepared according to a previously published
study(8,9). The structure is shown in Figure 1.
Figure 1. Structure of C60 fullerene derivative, PEG-C60 -3.

II. Cell Culture
Mouse neuroblast Neuro-2A cells were grown in
DMEM supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT, USA), 1.5 g/L sodium bicarbonate, 1% penicillin-streptomycin-amphocillin, 1% sodium pyrophosphate
and 1% non-essential amino acids at 37°C in a humidified
atmosphere with 5% CO2 for 24 h before proceeding with the
following experiments.
III. Cell Viability Assay
The MTT assay to test the cytotoxicity of reagents and
cell viability was carried out as described previously(10).
Cells (15,000 cells/well) were grown in supplemented culture
medium. The cells were treated with Aβ25-35 (0 - 15 μM) for
24 h, followed by the addition of MTT to the growing cultures
at a final concentration of 0.5 mg/mL. The absorbance was
measured with a spectrophotometer (Thermo Varioskan
Flash, Vantaa, Finland) at 560 nm.
IV. Intracellular
Measurement

Reactive

Oxygen

Species

(ROS)

Levels of cellular oxidative stress were measured
using the fluorescent probe, Dihydrorhodamine (DHR123),
as described previously(11). After treatment with these
compounds for 12 h, the cells were incubated for 30 min in
the presence of 20 µM of DHR123, followed by washing with
phosphate-buffered saline (PBS). DHR123 is trapped mainly
in the cytoplasm and is oxidized into highly fluorescent
rhodamine 123 by intracellular ROS. The DCF fluorescence
intensity of cells was measured using a confocal microscope
(Leica TCS SP5, Bensheim, Germany).
V. RNA Preparation and Complementary (c)DNA Chip
Analysis
Total RNAs were extracted from Neuro-2A cells
treated with or without 15 μM of Aβ25-35 for 24 h using the
TRI-reagent (Molecular Research Center, Cincinnati, OH,
USA) following the manufacturer’s instructions. Only RNA
samples with an OD 260/280 ratio of 1.7 - 2.0 were used for

the microarray. The expression data from the cDNA microarrays were initially analyzed using BeadScan software (Illumina, San Diego, CA, USA). For the BeadArray analysis, the
integrity of total RNA was assessed using the Agilent Bioanalyzer 2100 (Palo Alto, CA, USA), and RNA integrity (RIN)
scores greater than 9.5 were present in all samples. RNA was
amplified using the Illumina TotalPrep RNA amplification
kit (Ambion, Applied Biosystems, Foster, CA, USA) with an
in vitro transcription reaction period of 12 h. The quantity
and quality of biotinylated, amplified cRNA were assessed
using the Agilent Bioanalyzer 2100. Amplified cRNA at 1.5
μg per array was hybridized to Sentrix Mouse-6.v1 BeadChip
arrays (Illumina) according to the manufacturer's directions.
Hybridized BeadChip arrays were stained with Amersham
fluorolink streptavidin-Cy3. BeadChip arrays were scanned
with an Illumina BeadStation Scanner, and values with
detection scores were compiled using BeadStudio Version
1.5.1.3 (Illumina) for data analysis. Only probe sets with at
least a 1.5-fold change in gene expression compared to the
controls were examined for the manual classification analysis
using a gene ontology database (http://www.godatabase.org/
cgi-bin/amigo/go.cgi) and published reports(12).
VI. Statistical Analysis
Unless otherwise indicated, results are represented as
the mean ± SD of five replicates, and at least three separate
experiments were performed. One-way analysis of variance
(ANOVA) followed by Bonferroni's test was used to determine statistical significance for multiple comparisons, and
Student’s t-test was used between groups. A p value of less
than 0.05 was accepted as statistically significant.

RESULTS AND DISCUSSION
We evaluated the anti-cytotoxic effects of PEG-C60 -3 on
Aβ25-35-treated Neuro-2A cells. Treatment of Neuro-2A cells
with Aβ25-35 for 24 h decreased cell viability, as determined
by an MTT assay (Figure 2). Neuro-2A cells treated with
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Aβ25-35 (15 μM) for 24 h in the absence of test compounds
exhibited 60.7% viability; while viability of cells pretreated
with PEG-C60 -3 (5 - 15 μM) increased to 64.1%, 70.4% , and
86.0%, respectively. PEG-C60 -3 displayed significant protection against Aβ cytotoxicity.
ROS formation visualized by confocal microscopy with
the redox-sensitive fluorescent dye, DHR123 was shown in
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Figure 2. Cytoprotective effects of C60 fullerene derivatives against
β-amyloid (Aβ)25-35-induced toxicity of Neuro-2A cells. Cell viability
of combined treatments with Aβ 25-35 (15 μM) and C 60 fullerene
derivatives (0 - 15 μM) for 24 h. *** p < 0.001, versus Aβ treatment.
The results are presented as the mean ± SD (n = 5). Cell viability was
assessed by an MTT assay and one-way ANOVA followed by Bonferroni's test. The experiment is representative of more than three independent analyses with similar results.

Figure 3. Cells were located under bright-field optics and
scanned once with a laser (excitation at 488 nm and emission at 510 nm). The fluorescence was more intense in
Neuro-2A cells treated with Aβ25-35 alone, which meant it
contained more free radicals, compared to those treated with
PEG-C60 -3. The amount of ROS in Aβ-treated Neuro-2A
cells was reduced by the addition of PEG-C60 -3.
To further understand the gene expression profile upon
Aβ and C60 treatments in cells, a microarray experiment
was performed. The data obtained were the representative of more than 3 independent experiments with similar
results. Statistical tests and thresholds on fold changes were
commonly used for the identification of altered gene expression by microarray assays. The scatter plots in Figure 4
indicated, graphically, the correlation between the platforms.
BeadStudio Version 1.5.3.1 (Illumina) was used to analyze
the expression data of cDNA. The plot on the left was the
control versus PEG-C60 -3 treatment, and the plot on the right
showed the control versus Aβ-treatment. In general, there
was reasonably good concordance between the platforms.
One-point-five fold up- and down-regulated genes were
shown in dots (Figure 4). Only genes with at least 1.5-fold
changes were used to compare in the Venn diagrams (Figure
5). The Venn diagrams involved two sets: the left circle
represented Aβ-treatment and the right circle represented
PEG-C60 -3 treatment of Neuro-2A cells. Figure 5A showed
the number of down-regulated gene expression entities.
There were 89 entities with Aβ-treatment and 162 entities

Table 1. Differentially expressed genes in Neuro 2A cells after Aβ and C60 treatment
Gene name and function

Accession No.

Aβa

Aβ + C60

Asparagine synthetase (ASNS)

NM_012055.1

0.64

0.78

Activating transcription factor 5 (ATF5); RNA polymerase II transcription
factor activity

NM_030693.1

0.64

0.69

Voltage-dependent calcium channel gamma-3 subunit (CACNG3); voltage-gated
ion channel activity

NM_019430.1

0.61

0.77

Cyclin-dependent kinase inhibitor 1A( CDKN1A); protein kinase inhibitor
activity

NM_007669.2

0.64

0.80

NM_001081387.1

0.61

0.80

Insulin-like growth factor-binding protein 6 (IGFBP6); insulin-like growth
factor binding

NM_008344.1

0.66

0.73

Lung carcinoma derived myc gene (LMYC1); transcription factor activity

NM_008506.2

0.63

0.76

Transcriptional repressor (CTCFL); nucleic acid binding

Myeloid differentiation primary response (MYD116); cell differentiation

NM_008654.1

0.54

0.70

Neoplastic progression 3 (NPN3); antioxidative activity

NM_029688.2

0.63

0.75

Nuclear RNA export factor 7(NXF7); transferase activity

NM_130888.1

0.61

0.73

Oral-facial-digital syndrome 1 protein (OFD1); molecular_function

NM_177429.2

0.67

0.87

Insulin gene enhancer protein (ISL1); sequence-specific DNA binding

NM_021459.2

1.66

1.33

AK052579

1.72

1.28

Paired mesoderm homeobox gene (PMX2B); transcription factor
Ribosomal protein S28 (RPS28); ribonucleoprotein complex

NM_016844.1

1.56

0.77

Tissue inhibitor of metalloproteinases 2 (TIMP2); metalloproteinase inhibitor 2

NM_011594.2

1.64

1.39

Transient receptor potential cation channel, subfamily M, member 2 (TRPM2);
hydrolase activity

NM_138301.1

1.52

1.18

*a: up-regulated gene expression > 1.5-fold change (ratio > 1.5); down-regulated gene expression > 1.5-fold change (ratio < 0.66)
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Figure 3. Effects of PEG-C60 -3 on β-amyloid (Aβ)25-35-induced intracellular oxidative stress in Neuro-2A cells. DHR123 fluorescence imaged
by laser confocal microscopy with treatments of vehicle control (0.1% DMSO) (left), Aβ25-35 (15 μM) alone (middle), and a combination of
Aβ25-35 and PEG-C60 -3 (10 μM) for 12 h (right). bar = 25 μm.
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Figure 4. Scatter plot of 1.5 fold up- and down- regulated gene expression for microarray assay. Scatter plot analysis was determined by BeadStudio Version 1.5.1.3 (Illumina). RNA samples with an OD 260/280 ratio of 1.7 - 2.0 were used for the microarray. The quantity and quality of
biotinylated, amplified cRNA were assessed using the Agilent Bioanalyzer 2100.

with PEG-C60 -3 treatment; nevertheless, they corresponded
to points in the area where two circles overlapped, which were
57 down-regulated entities. The up-regulated gene expression was shown in Figure 5B. Fifty-one entities were treated
with Aβ, whereas 105 entities were treated with PEG-C60 -3.
The overlapping area of the two circles comprised 16 entities,
which were up-regulated with both treatments.
We observed the treatment of Neuro-2A cells with
Aβ-induced alterations of several gene expressions. The

expressions of 32 down-regulated and 35 up-regulated gene
entities were further correlated to their known biological
functions using gene ontology databases. Table 1 showed the
genes and their descriptions in Aβ and PEG-C60 -3 treatment.
These included genes coding for transcription factor, growth
factor, ion-channel, transferase and cell differentiation
activity. Aβ was known to induce intracellular oxidative stress
by upregulating ROS production and causing mitochondrial
membrane aberrations in nerve cells. The increased level of
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(A)

Entity List 1: Fold change >=
1.5 custom selection [Abeta]
vs [none] down
89 entities

Entity List 2: Fold change >=
1.5 custom selection [A] vs
[none] down
162 entities

(B)

Entity List 1: Fold change >=
1.5 custom selection [Abeta]
vs [none] up
51 entities

Entity List 2: Fold change >=
1.5 custom selection [A] vs
[none] up
105 entities

Figure 5. Venn diagram with the number of genes present in each
platform and genes in common between platforms. (A) shows the
number of down-regulated gene expression entities; (B) shows the
number of up-regulated gene expression entities. BeadChip arrays
were scanned with an Illumina BeadStation Scanner and values with
detection scores were compiled using BeadStudio Version 1.5.1.3
(Illumina) for data analysis. Only probe sets with at least a 1.5-fold
change in gene expression compared to the controls were examined
for the manual classification analysis using a gene ontology database.

oxidative stress in the AD brain is reflected by the increased
brain content of iron (Fe) and copper (Cu), both capable of
stimulating free radical formation, increasing protein and
DNA oxidation in the AD brain, enhancing lipid peroxidation, decreasing the level of cytochrome c oxidase and
advanced glycation end products (AGEs), carbonyls, malondialdehyde (MDA), peroxynitrite and heme oxygenase-1
(HO-1). AGEs, mainly through their interaction with receptors for AGEs (RAGEs), further activate signaling pathways
and induce the formation of pro-inflammatory cytokines,
such as interleukin-6 (IL-6)(13) .
With Aβ treatment, gene expressions with a ratio greater
than 1.5 were up-regulated genes and those having a ratio
smaller than 0.66 were down-regulated genes (Table 1). Transcription from the ASNS gene was increased in response to
either amino acid (amino acid response) or glucose (ER stress
response) deprivation(14). Transcription factors ATF4 and
ATF3 bound to the upstream region of the ASNS (asparagine
synthetase) gene were functioned as mammalian ER-stressresponsive sequences(15). ATF5 ER stress-related genes are
bZIP transcription factors that forms homodimers, which,
at least in vitro, bind to the cAMP response element (CRE).
In addition, ATF5 represses cAMP-induced transcription
in intact cells(16,17) and has been shown to inhibit apoptosis(18). Available evidence suggests that genes encoding
brain expressed voltage-gated calcium channels, including
CACNG3 on chromosome, may represent susceptibility
loci for CAE (childhood absence epilepsy)(19) and neuron

cells in this study. Cyclin-dependent kinase inhibitor 1A
(CDKN1A) is implicated in the regulation of cell growth
and cell response to DNA damage(20). It also plays a role in
the protection of cells against apoptosis and its expression
is essential to maintain cell survival during differentiation
of several cell lineages(21). The CTCF-like protein, CTCFL,
is a DNA-binding factor that regulates the transcriptional
program of mammalian male germ cells(22). It is also pivotal
for the up-regulation of APP (amyloid precursor protein)
expression during synaptogenesis in primary neurons(23).
Over-expression of IGFBP-6 significantly suppresses the
proliferation, invasion and metastatic activity of NPC (nasopharyngeal carcinoma) cells and increases their apoptosis(24).
Lmyc 1 gene encodes for a transcription factor that is believed
to regulate expression of 15% of all genes(25). This means
that in addition to its role as a classical transcription factor,
Myc also regulates global chromatin structure by regulating
histone acetylation both in gene-rich regions and at sites far
from any known gene(26). MYD116 (also known as gadd34)
is the murine homologue of growth arrest- and DNA damageinducible genes, a gene family implicates in growth arrest and
apoptosis induced by endoplasmic reticulum dysfunction(27);
hence, it was reported to influence cell survival(28). Peroxiredoxins (Prx) are neuroprotective enzymes that protect
neurons against oxidative stress. However, they can be inactivated through hyperoxidation of their active site cysteine,
taking place in the brain in response to oxidative insults,
such as stroke and aging. Sulfiredoxin (Srxn1), also known as
neoplastic progression protein 3 (Npn3), is an inducible gene
whose expression promoted the reduction of hyperoxidized
Prx and protection against peroxide-induced death(29). NPN3
(SRXN1) enzyme is involved in antioxidant metabolism by
re-activating peroxiredoxins, which are a group of peroxidases, when these enzymes are inhibited by over-oxidation(30).
It is upregulated by an exceptionally large fold-magnitude in
microarray studies of oxidative stress(31). Nuclear RNA export
factor 7 (NXF7) associates with translating ribosomes, stress
granules (SGs) and processing bodies (P-bodies), the latter
two of which are believed to be cytoplasmic sites of storage,
degradation and/or sorting of mRNAs(32). OFD1, a prolyl
4-hydroxylase-like 2-oxoglutarate dioxygenase, controls
the oxygen-dependent stability of Sre1N. In the presence of
oxygen, OFD1 accelerates the degradation of Sre1N, but under
low oxygen, it is inhibited and Sre1N accumulates. Sre1, the
fission yeast sterol regulatory element-binding protein, is an
ER membrane-bound transcription factor that controls adaptation to low oxygen growth(33). Oral-facial-digital syndrome
type I (OFD1 mutation) is associated with the dysfunction of
primary cilia, a microtubule-based cellular projection that
mediates multiple signaling pathways. Centrioles represent
the principal microtubule organizing centers of animal cells
and Ofd1 acts at the distal centriole to stabilize centriolar
microtubules at a defined structure and length and reveals the
importance of centriole length control in centrosome function(34). The above mentioned genes exhibited greater than
1.5-fold changes with down-regulated expression. PEG-C60-3
co-treatment reversed the changes in gene expression.
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Transcription factor, Islet1 (ISL1) is a neuronal differentiation marker(35) that was reported to be associated with
motor-axon differentiation(36). PMX2B is also a transcription factor that plays an important role in the development of
oculomotor nerves and regulates the expression of both tyrosine hydroxylase and dopamine beta-hydroxylase genes(37).
Ribosomal protein S28 (RPS28) gene encodes a ribosomal
protein that is a component of the 40S sub-unit. The protein
belongs to the S28E family of ribosomal proteins. The 5’
leader regions of RPS28 mRNAs are found to harbour 8-11
pyrimidine tracts, which suggest similarities to regulatory
stretches that control the translation of mRNAs for ribosomal
proteins in animals(38). R-protein depletion, with a few exceptions, leads to the accumulation of specific rRNA precursors,
highlighting their individual roles in rRNA processing(39).
A stress, virus infection, triggers tissue inhibitor of matrix
metalloproteinase 2 (TIMP2) upregulation in hepatic cells(40),
and the upregulated TIMP2 is reported to be associated with
the neuroprotection against hyperoxic damage(41). TIMP2
seemed to be elicited upon amyloid-beta treatment in Neuro2A cells (1.64 fold), while PEG-C60-3 co-treatment reduced
the stress-induced protective mechanism. TRPM2, a type of
Nudix hydrolase, is a plasma membrane channel for Ca2+ and
Na+ flowing into the neuronal cell. It is activated by oxidative
stress, mediated cell death and inflammation, and was reported
to be related to H2O2 and amyloid β-peptide induced striatal
cell death(42). In this study, PEG-C60-3 and Aβ co-treatment
could reverse amyloid β-peptide induced TRPM2-upregulation. Aβ-treated cells trigger the signaling cell cycle stimulating repair and protect cells to avoid cell apoptosis through
the changes of gene expression. The above mentioned genes
exhibited greater than 1.5-fold changes with up-regulated
expression with Aβ treatment. C60 co-treatment reversed the
changes in gene expression. These results suggested that C60
showed a reverse effect on Aβ-treated Neuro-2A cells.
In summary, we used oligonucleotide microarrays to
identify and profile the expression of genes in Neuro-2A
cells upon Aβ and PEG-C60 -3 co-treatment. In response to
Aβ exposure for 24 h, 16 up-regulated and down-regulated
genes were elucidated to correlate the cytoprotective effect
of PEG-C60 -3 that might result from intracellular oxidative
stress alleviation, ion-channel and transporter homeostasis,
cell cycle regulation, and modulation in transcription factor
activity thus protected from cell apoptosis.
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